


COVID-19 Vaccination Schedule for Most People (People who are NOT Moderately or Severely Immunocompromised)




People ages 6 months through 4 years

Moderna




-OR-

Pfizer-BioNTech




People ages 5 through 11 years

Moderna




-OR-

Pfizer-BioNTech



People ages 12 years and older

Moderna, Novavax, or Pfizer-BioNTech



People ages 18 years and older who previously received Janssen primary series dose†



For more specific clinical guidance, see:

- [Pre-exposure prophylaxis](#)
- [Interim COVID-19 Immunization Schedule](#)
- [Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Approved or Authorized in the United States](#)

Note: This schedule does not include clinical details necessary for administering COVID-19 vaccines. For clinical details, see the resources at the end of this document.

* The bivalent booster dose is administered at least 2 months after completion of the primary series. For people who previously received a monovalent booster dose(s), the bivalent booster dose is administered at least 2 months after the last monovalent booster dose.


† Janssen COVID-19 Vaccine should only be used in certain limited situations. See: <https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us-appendix.html#appendix-a>

COVID-19 Vaccination Schedule for People Who Are Moderately or Severely Immunocompromised




People ages 6 months through 4 years

Moderna




-OR-

Pfizer-BioNTech




People ages 5 years through 11 years

Moderna



-OR-

Pfizer-BioNTech



For more specific clinical guidance, see:


- [Pre-exposure prophylaxis](#)
- [Interim COVID-19 Immunization Schedule](#)
- [Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Approved or Authorized in the United States](#)

COVID-19 Vaccination Schedule for People Who Are Moderately or Severely Immunocompromised




People ages 12 years and older

Moderna or Pfizer-BioNTech




Novavax




-OR-

People ages 18 years and older who previously received Janssen primary series dose†



Monoclonal antibodies (EVUSHELD™) for COVID-19 pre-exposure prophylaxis

People ages 12 years and older (must weigh at least 40kg)



For more specific clinical guidance, see:

- [Pre-exposure prophylaxis](#)
- [Interim COVID-19 Immunization Schedule](#)
- [Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Approved or Authorized in the United States](#)

Note: This schedule does not include clinical details necessary for administering COVID-19 vaccines. For clinical details, see the resources at the end of this document.

* The bivalent booster dose is administered at least 2 months after completion of the primary series. For people who previously received a monovalent booster dose(s), the bivalent booster dose is administered at least 2 months after the last monovalent booster dose.

† Janssen COVID-19 Vaccine should only be used in certain limited situations. See: <https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us-appendix.html#appendix-a>